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Background: Glutamate decarboxylase 1 (GAD1), a rate-limiting enzyme in the production of γ-aminobutyric acid
(GABA), is found in the GABAergic neurons of the central nervous system. Little is known about the relevance of
GAD1 to oral squamous cell carcinoma (OSCC). We investigated the expression status of GAD1 and its functional
mechanisms in OSCCs.
Methods: We evaluated GAD1 mRNA and protein expressions in OSCC-derived cells using real-time quantitative
reverse transcriptase-polymerase chain reaction (qRT-PCR) and immunoblotting analyses. To assess the critical
functions of GAD1, i.e., cellular proliferation, invasiveness, and migration, OSCC-derived cells were treated with the
shRNA and specific GAD1 inhibitor, 3-mercaptopropionic acid (3-MPA). GAD1 expression in 80 patients with primary
OSCCs was analyzed and compared to the clinicopathological behaviors of OSCC.
Results: qRT-PCR and immunoblotting analyses detected frequent up-regulation of GAD1 in OSCC-derived cells
compared to human normal oral keratinocytes. Suppression of nuclear localization of β-catenin and MMP7 secretion
was observed in GAD1 knockdown and 3-MPA-treated cells. We also found low cellular invasiveness and migratory
abilities in GAD1 knockdown and 3-MPA-treated cells. In the clinical samples, GAD1 expression in the primary OSCCs
was significantly (P < 0.05) higher than in normal counterparts and was correlated significantly (P < 0.05) with
regional lymph node metastasis.
Conclusions: Our data showed that up-regulation of GAD1 was a characteristic event in OSCCs and that GAD1 was
correlated with cellular invasiveness and migration by regulating β-catenin translocation and MMP7 activation.
GAD1 might play an important role in controlling tumoral invasiveness and metastasis in oral cancer.
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Oral squamous cell carcinomaBackground
Glutamate decarboxylase 1 (GAD1) catalyzes production
of γ-aminobutyric acid (GABA) from L-glutamic acid, the
principal inhibitory neurotransmitter in the brain [1,2].
GAD1 is associated with development of insulin-dependent
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reproduction in any medium, provided the orsyndrome [4]. The murine model of cleft palate also lacks
GAD1 expression [5].
GAD1 is related closely to β-catenin expression by
microarray analysis in ovarian endometrioid adenocar-
cinoma and Wilms’ tumor [6,7], whereas the functional
interaction between GAD1 and β-catenin has not been
demonstrated clearly. β-catenin is an essential component
of both intercellular junctions and the canonical Wnt sig-
naling pathway and connects the adherens junction com-
plex with the actin cytoskeleton that binds directly to the
intracellular domain of E-cadherin [8]. Disruption ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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invasiveness, proliferation, and migration [9-11].
The Wnt/β-catenin pathway is activated when the Wnt
ligand binds to cell-surface receptors, the Frizzled family re-
ceptor, and the LRP 5/6 co-receptor. Activation of this
pathway leads to inhibition of a complex comprising aden-
omatous polyposis coli, axis inhibition protein, and glyco-
gen synthase kinase 3β. This complex has functions is
involved in phosphorylation and degradation of β-catenin
by the ubiquitin/proteosome system. After activation of the
Wnt/β-catenin pathway, β-catenin translocates to the nu-
cleus for binding to T-cell factor/lymphoid enhancer factor
(TCF/LEF) and activates transcription of Wnt-targeting
genes [12].
MMP7 is a Wnt-targeting gene that has been detected
in several cancers, such as prostate, colon, stomach, lung,
and breast [13-17] and degrades components of the extra-
cellular matrix (ECM), including collagens (I, III, IV, and
V), fibronectin, vitronectin, laminin, and elastin [18]. In
the oral region, Chuang et al. demonstrated that MMP7 is
closely related to invasion in OSCCs of buccal mucosa
[19]. Therefore, MMP7 contributes significantly to the cel-
lular invasiveness and metastasis of tumors.
The current study found that GAD1 is overexpressed
frequently in OSCC-derived cell lines, and that GAD1
knockdown affects cellular invasiveness and migration.
Based on this evidence, we proposed that GAD1 might
be a therapeutic target to prevent metastasis in OSCCs.
Methods
Ethics statement
The Ethics Committee of the Graduate School of Medicine,
Chiba University (approval number, 236) approved the
study protocol, which was performed according to the
tenets of the Declaration of Helsinki. All patients provided
written informed consent.
OSCC-derived cell lines and tissue samples
RIKEN BRC (Ibaraki, Japan) provided the Sa3, HO-1-u-1,
KOSC-2, Ca9-22, HO-1-N-1, HSC-2, and HSC-3 cell lines
through the National Bio-Resource Project of the MEXT,
Tokyo, Japan. Short tandem repeat profiles confirmed the
cellular identity. Primary cultured human normal oral ker-
atinocytes (HNOKs) were used as normal controls [20,21].
All cells were grown in Dulbecco’s modified Eagle’s med-
ium (DMEM) (Sigma, St. Louis, MO) supplemented with
10% fetal bovine serum (FBS) (Sigma) and 50 units/ml of
penicillin and streptomycin (Sigma). Primary OSCCs and
patient-matched normal oral epithelial samples were ob-
tained during surgical resections of the tumors with sim-
ultaneous neck dissection at Chiba University Hospital.
The average age of the patients was 64.6 years (range, 27–
90 years). The mean follow-up time for all of the patients
was 68.5 months (range, 24–98 months). The resectedtissues were fixed in 10% buffered formaldehyde solu-
tion for pathological diagnosis and immunohistochem-
istry (IHC). Histopathological diagnosis of each tissue
was performed according to the tumor-node-metastases
classification of the International Union against Cancer.
Preparation of cDNA
Total RNA was isolated using TRIzol Reagent (Invitrogen,
Carlsbad, CA). cDNA was generated from 5 μg of total
RNA using Ready-To-Go You-Prime First-Strand Beads
(GE Healthcare, Buckinghamshire, UK) and oligo (dT)
primer (Sigma Genosys, Ishikari, Japan).
mRNA expression analysis
Real-time quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) was performed using a Light
Cycler 480 apparatus (Roche Diagnostics GmbH, Mannheim,
Germany) to evaluate the expression levels of GAD1 mRNA
in the seven OSCC-derived cell lines (HSC-2, HSC-3,
Sa3, HO-1-u-1, HO-1-N-1, KOSC-2, and Ca9-22) and
HNOKs. Primers were designed using the Probe Finder
qRT-PCR assay design software (available at www.universal-
probelibrary.com). The sequences of the gene-specific pri-
mers and universal probes were as follows: GAD1 forward,
5′-CCATGG TCG TAC CTG ACT CC-3′ and reverse, 5′-
CCT GGA ACT GGC TGA ATA CC-3′ (probe #78);
MMP7 forward, 5′-TCT CCT CCG AGA CCT GTC C-3′
and reverse, 5′-GCT GAC ATC ATG ATT GGC TTT-3′
(probe #72); and β-catenin forward, 5′-GCT TTC AGT
TGA GCT GAC CA-3′ and reverse, 5′-CAA GTC CAA
GAT CAG CAG TCT C-3′ (probe #21). The PCR reactions
were carried out in a final volume of 20 μl of a reaction
mixture comprised of 10 μl of Light Cycler 480 Probes
Master (Roche), 0.2 μl of universal probe (Roche), and
4 μM of the primers. The reaction mixture was loaded onto
the PCR plate and subjected to an initial denaturation at
95°C (10 min), followed by 45 rounds of amplification at
95°C (10 sec) for denaturation, 60°C (30 sec) for annealing,
and 72°C (1 sec) for extension, followed by a cooling step at
50°C for 30 seconds. The transcript amounts for the GAD1
and other genes were estimated from the respective stand-
ard curves and normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) forward, 5′-AGCCACATCGCT
CAGACAC-3′ and reverse, 5′-GCCCAATACGACCAAAT
CC-3′ (probe #60) transcript amounts determined in corre-
sponding samples.
Protein extraction
The cells were washed twice with cold phosphate buffered
saline (PBS) and centrifuged briefly. The cell pellets were
incubated at 4°C for 30 min in a lysis buffer (7 M urea,
2 M thiourea, 4% w/v CHAPS, and 10 mM Tris pH 7.4)
with a proteinase inhibitor cocktail (Roche) to extract
whole cell lysates. The protein concentrations of whole cell
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Richmond, CA). Cytoplasmic and nuclear fractions from
cultured cells were isolated using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Thermo, Rockford, IL).
The protein concentrations were measured using the BCA
Protein Assay Kit (Thermo).
Immunoblotting
Protein extracts were electrophoresed on 4% to 12%
Bis-Tris gel, transferred to nitrocellulose membranes
(Invitrogen), and blocked for 1 hr at room temperature with
Blocking One (Nacalai Tesque, Inc., Kyoto, Japan). The
membranes were washed three times with 0.1% Tween-20
in Tris-buffered saline and incubated with antibody
for GAD1 (Santa Cruz Biotechnology, Dallas, TX) and
β-catenin (Novus Biologicals, Littleton, CO) overnight at 4°C
and GAPDH (Thermo) for 1 hr at room temperature.
The membranes were washed again and incubated
with a anti-rabbit or anti-mouse IgG horseradish peroxidase
conjugate (Promega, Madison, WI) as a secondary antibody
for 1 hr at room temperature. Finally, the membranes were
detected using SuperSignal West Pico Chemiluminescent
Substrate (Thermo), and immunoblotting was visualized
by exposing the membranes to ATTO Light-Capture II
(ATTO, Tokyo, Japan). Signal intensities were quantitated
using the CS Analyzer version 3.0 software (ATTO).
IHC
IHC of 4-μm sections of paraffin-embedded specimens was
performed using mouse anti-GAD1 monoclonal antibody
(Santa Cruz Biotechnology). Briefly, after deparaffinization
and hydration, the endogenous peroxidase activity was
quenched by a 30-min incubation in a mixture of 0.3%
hydrogen peroxide solution in 100% methanol, after which
the sections were blocked for 2 hr at room temperature
with 1.5% blocking serum (Santa Cruz Biotechnology) in
PBS before reaction overnight with anti-GAD1 antibody
(1:100 dilution) at 4°C in a moist chamber. Upon incu-
bation with the primary antibody, the specimens were
washed three times in PBS and treated with Envision
reagent (DAKO, Carpinteria, CA) followed by color de-
velopment in 3,3′-diaminobenzidine tetrahydrochloride
(DAKO). The slides then were lightly counterstained with
hematoxylin, dehydrated with ethanol, cleaned with xy-
lene, and mounted. To avoid non-specific binding, an im-
munizing peptide blocking experiment was performed. As
a negative control, triplicate sections were immunostained
without exposure to primary antibodies. To quantify the
status of the GAD1 protein expression in those compo-
nents, we used an IHC scoring system to quantitatively
evaluate the IHC staining, described previously [22-24].
We counted 300 cells/one field of vision. The staining in-
tensity (0, negative; 1, weak; 2, moderate; 3, intense) and
the number of positive cells in the field of vision thenwere multiplied to calculate the IHC score using the for-
mula: IHC score = 0 × (number of negatively stained cells
in the field) + 1 × (number of weakly stained cells in the
field) + 2 × (number of moderately stained cells in the
field) + 3 × (the highest score for normal tissue). Cases
with a GAD1 IHC score exceeding 103 (maximal score
within +3 standard deviations of the mean of normal tis-
sues) were defined as GAD1-positive. Two independent
pathologists, both masked to the patients’ clinical status,
made these judgments.
Stable transfection of GAD1 shRNA
A total of 2 × 105 OSCC-derived cells (HSC2 and HSC3)
were seeded into each well of 6-well plates in DMEM F-12
HAM (Sigma) containing 10% FBS (Sigma) without antibi-
otics. GAD1 shRNA (shGAD1, Santa Cruz Biotechnology)
and the control shRNA (mock, Santa Cruz Biotechnology)
vectors were transfected into OSCC-derived cells with
Lipofectamine LTX (Invitrogen) and Plus Reagents
(Invitrogen). After transfection, the cells were isolated
using a culture medium containing 2 μg/mL Puromycin
(Invitrogen). After 3 to 4 weeks, resistant cell clones were
picked and transferred to 6-well plates and expanded
gradually to 10-cm dishes. At 90% confluence, qRT-PCR
and immunoblotting were performed to assess the
efficiency of GAD1 knockdown.
3-Mercaptopropionic acid (3-MPA) treatment
To study the effect of decreased GAD1 activity, we used
3-MPA, a strong competitive inhibitor, at the active GAD1
site [25]. Because several studies has reported that the Ki
of 3-MPA ranges from 2.7 to 5.1 μM [26-28], we used 3-
MPA (Sigma) at a concentration of 5 μM for functional
analyses.
Cellular growth
To evaluate the effect of GAD1 knockdown on cellular
proliferation, we analyzed cellular growth in shGAD1 and
mock cells. These transfectants were seeded in 6-well
plates at a density of 1 × 104 viable cells/well. The experi-
ments were carried out for 168 hr, and the cells were
counted every 24 hr. At the indicated time point, the cells
were trypsinized and counted using a hemocytometer in
triplicate samples. We also performed a cellular growth
assay using 3-MPA-treated cells.
Invasiveness assay
We evaluated the effect of GAD1 knockdown on cellular
invasiveness. A total of 2.5 × 105 cells were seeded on a
polyethylene terephthalate membrane insert with a pore
size of 3 μm in a transwell apparatus (Becton-Dickinson
Labware, Franklin Lakes, NJ). In the lower chamber, 1 ml
of DMEM with 10% FBS was added. After the cells were



















































































Figure 1 Evaluation of GAD1 expression in OSCC-derived cell lines. a Quantification of GAD1 mRNA levels in OSCC-derived cell lines by qRT-PCR
analysis. All OSCC-derived cell lines have significant up-regulation of GAD1 mRNA compared with that in the HNOKs. Data are expressed as the mean ±
SEM of values from three assays (*P< 0.05, Mann–Whitney U test). b Immunoblotting analysis of GAD1 protein in the OSCC-derived cell lines and HNOKs.
GAD1 protein expressions are up-regulated in all OSCC-derived cell lines examined compared with that in the HNOKs. c Evaluation of GAD1 protein
expression in primary OSCCs representative IHC results for GAD1 protein in normal tissue and primary OSCC. Original magnification, ×400. Scale bars,
10 μm. Strong GAD1 immunoreactivity is detected in primary OSCCs. Normal oral tissues show almost weak immunostaining. d The status of GAD1 protein
expression in normal oral tissues and primary OSCCs (n = 80). The GAD1 IHC scores for normal oral tissues and OSCCs range from 15 to 103 (median, 52)
and 71 to 230 (median, 145), respectively. GAD1 protein expression levels in OSCCs are significantly (*P< 0.001, Mann–Whitney U test) higher than in
normal oral tissues.
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moved with a cotton swab. Cells adhering to the lower
surface of the membrane were fixed with methanol and
stained with crystal violet. The numbers of cells invading
the pores in five random fields were counted using a light
microscope at × 100 magnification. We also performed
























































shGAD1 and mock cells were seeded in a 6-well plate
until they reached full confluence in a monolayer. One
wound was created in the middle of each well using a
micropipette tip. The plate was incubated at 37°C at 5%
CO2. The results were visualized by measuring the wound
spaces. The mean value was calculated from data obtained
from three separate chambers. We also performed a mi-
gratory assay using 3-MPA-treated cells.GAPDH GAPDH
GAD1 GAD1
Figure 2 Expression of GAD1 in GAD1 knockdown cells.
qRT-PCR shows that GAD1 mRNA expression in the shGAD1 cells
(HSC2 and HSC3-derived transfectants; 2 clones each) are significantly
lower than that in the mock cells (*P < 0.05, Mann–Whitney U test).
Immunoblotting analysis shows that the GAD1 protein levels in
shGAD1 cells (HSC2 and HSC3-derivrd transfectants; 2 clones each)
have decreased markedly compared with that in mock cells.Casein zymography
The cells were cultured in serum-free DMEM for 48 hr.
The cell culture media were then concentrated using
Centrifugal Filter Units (Merck Millipore, Billerica, MA).
The concentrated proteins were loaded on precast 12%
Novex zymogram blue casein gels (Invitrogen) to mea-
sure MMP-7 proteolytic activity. After electrophoresis,
the gels were renatured in Novex Zymogram Renaturing
Buffer (Invitrogen) for 30 min at room temperature and
then incubated at 37°C in Novex Zymogram Developing
Buffer (Invitrogen) to allow degradation of the substratein the gel matrix. Enzymatic activity was visualized as a
clear band against a blue background [29-31].
Statistical analysis
Statistical significance was determined using Fisher’s exact






























































































































Figure 3 (See legend on next page.)
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Figure 3 GAD1 knockdown cells suppress translocation of β-catenin to the nucleus and MMP7 activation. a Immunoblotting analysis of
β-catenin in the nucleus of shGAD1 cells. The expression of β-catenin in the nucleus of shGAD1 cells has decreased markedly compared with that
in mock cells. β-catenin expression in the cytoplasm does not differ significantly between shGAD1 cells and mock cells. b Quantification of MMP7
mRNA levels in shGAD1 cells by qRT-PCR analysis. MMP7 mRNA is significantly down-regulated in shGAD1 cells compared with mock cells. c Casein
zymography analysis of MMP7 activity in shGAD1. Cell culture media are collected and concentrated, MMP7 activity is analyzed by casein zymography.
MMP7 secretion is decreased significantly in shGAD1 cells compared with mock cells.
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Results
Evaluation of GAD1 expression in OSCC-derived cell lines
We performed qRT-PCR and immunoblotting using OS
CC-derived cell lines (Sa3, HO-1-u-1, KOSC-2, Ca9-22,
HO-1-N-1, HSC-2, and HSC-3) and HNOKs (Figure 1a, b).
GAD1 mRNA was significantly (P < 0.05) up-regulated in






















































Figure 4 Functional analyses of GAD1 knockdown cells. a Invasiveness ass
invading the pores is counted (×100 magnification). The numbers penetrating t
compared with mock cells. Scale bars, 100 μm. b Migratory assay of shGAD1 ce
test) in the culture of mock cells after 8 hr, whereas there is still a gap in the shGFigure 1b shows representative results of immunoblotting
analysis of GAD1 (67 kDa). All OSCC-derived cell lines had
a significant (P < 0.05) increase in GAD1 protein expression
compared with the HNOKs. Expression analyses indicated
that both transcription and translation products of this
molecule were highly expressed in OSCC-derived cell lines.
Evaluation of GAD1 expression in primary OSCCs
We analyzed the GAD1 protein expression in primary
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Figure 5 (See legend on next page.)
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Figure 5 3-MPA-treated cells suppress translocation of β-catenin to the nucleus and MMP7 activation. a Immunoblotting analysis of β-catenin
in the nuclei of 3-MPA-treated cells. β-catenin expression in the nucleus of 3-MPA-treated cells is decreased markedly compared with that in control
cells. β-catenin expression in the cytoplasm does not differ significantly between 3-MPA-treated cells and control cells. b Quantification of MMP7 mRNA
level in 3-MPA-treated cells by qRT-PCR analysis. MMP7 mRNA is significantly down-regulated in 3-MPA-treated cells compared with control cells. c Casein
zymography analysis of MMP7 activity in 3-MPA-treated cells. Cell culture media are collected and concentrated, MMP7 activity is analyzed by casein
zymography. MMP7 secretion is decreased significantly in 3-MPA-treated cells compared with control cells.
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tive IHC results for GAD1 protein in normal oral tissues
and primary OSCCs. Strong GAD1 immunoreactions were
detected in the cytoplasm in the OSCCs. The GAD1
IHC scores for normal oral tissues and OSCCs ranged
from 15 to 103 (median, 52) and 71 to 230 (median, 145),
respectively. The GAD1 IHC score in primary OSCCs wasFigure 6 Functional analysis of the 3-MPA-treated cells. a Invasiveness as
cells invading the pores are counted (×100 magnification). The numbers pene
U test) greater compared with control cells. Scale bars, 100 μm. b Migratory as
(*P < 0.05, Mann–Whitney U test) in the culture of control cells after 8 hr, wher
×100. Scale bars, 100 μm.significantly (P < 0.001) higher than in normal oral tissues
(Figure 1d).
Establishment of GAD1 knockdown cells
To assess the GAD1 functions in oral cancer, shRNA
transfection was carried out in the OSCC-derived cells
(HSC2 and HSC3). Expressions of GAD1 mRNA andsay of the 3-MPA-treated cells. After crystal violet staining, the numbers of
trating the 3-MPA-treated cells are significantly (*P< 0.05, Mann– Whitney
say of 3-MPA-treated cells. The wound area is decreased significantly
eas there is still a gap in the 3-MPA-treated cells. Original magnification,
Table 1 Correlation between GAD1 expression and
clinical classification in OSCC
Clinical classification Total Result of immunostaining P value
No. of patients (%)
GAD1 (high) GAD1 (low)
Age at surgery
< 60 17 15 (88%) 2 (12%) 0.527
≧ 60 63 52 (83%) 11 (17%)
Gender
Male 34 29 (85%) 5 (15%) 0.401
Female 46 38 (83%) 8 (17%)
T-primary tumor size
T1 8 6 (75%) 2 (25%) 0.263
T2 48 38 (79%) 10 (21%)
T3 14 13 (93%) 1 (7%)
T4 10 10 (100%) 0 (0%)
N-regional lymph node
N (negative) 48 36 (75%) 12 (25%) 0.011*
N (positive) 32 31 (97%) 1 (3%)
Stage
I 8 6 (75%) 2 (25%) 0.075
II 40 30 (75%) 10 (25%)
III 20 19 (95%) 1 (5%)
IV 12 12 (100%) 0 (0%)
Histopathlogical type
Well 54 46 (85%) 8 (15%) 0.441
Moderately 16 14 (88%) 2 (12%)
Poorly 10 7 (70%) 3 (30%)
Tumor site
Gingiva 20 18 (90%) 2 (10%) 0.243
Tongue 52 44 (85%) 8 (15%)
Buccal mucosa 4 2 (50%) 2 (50%)
Oral floor 4 3 (75%) 1 (25%)
GAD1(high), up-regulated GAD1; GAD1 (low), down-regulated GAD1; * P < 0.05.
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than in mock cells (Figure 2).
Functional analyses of GAD1 knockdown cells
β-catenin, which is located along the cell membrane and
cytoplasm in normal epithelial cells, is involved in cellular
adhesion and migration [32]. In cancer epithelial cells, β-
catenin is translocated into the nucleus, which activates
oncogenes including MMP-7 [33]. To assess the transloca-
tion of β-catenin in shGAD1 cells, we performed im-
munoblotting analysis using shGAD1 and mock cells. The
expression of β-catenin in the nucleus was suppressed in
shGAD1 cells compared with mock cells. The expressions
of β-catenin in the cytoplasm did not differ significantly
between the shGAD1 and mock cells (Figure 3a). To eval-
uate the MMP7 mRNA expression, we also performed
qRT-PCR using shGAD1 and mock cells. The expression
of MMP7 mRNA decreased significantly in shGAD1 cells
compared with mock cells (Figure 3b). Using casein zymo-
graphy, we also detected secreted MMP7 in shGAD1 and
mock cells. The MMP7 secretion was suppressed signifi-
cantly (P < 0.05) in shGAD1 cells compared with mock
cells (Figure 3c).
We also performed cellular proliferation, invasiveness,
and migratory assays to evaluate the biologic effects of
shGAD1 cells. A cellular proliferation assay showed similar
growth curves for shGAD1 and mock cells, indicating that
down-regulation of GAD1 did not affect cellular prolifera-
tion (data not shown). The invasiveness assay showed that
the number of penetrating shGAD1 cells decreased com-
pared with mock cells (Figure 4a). The migratory assay
showed that the wounds in the shGAD1 cells closed later
than in the mock cells when we visually monitored the area
of uniform wounds in confluent cell cultures (Figure 4b).
Functional analyses of 3-MPA-treated cells
We also performed functional analysis using 3-MPA. To as-
sess the translocation of β-catenin in 3-MPA-treated cells,
we performed immunoblotting analysis using 3-MPA-
treated and control cells. The expression of β-catenin in the
nucleus was suppressed in 3-MPA-treated cells. The ex-
pression of β-catenin in the cytoplasm did not differ signifi-
cantly between the 3-MPA-treated cells and control cells
(Figure 5a). To evaluate the MMP7 mRNA expression, we
also performed qRT-PCR using 3-MPA-treated and control
cells. The MMP7 mRNA expression decreased significantly
in the 3-MPA-treated cells compared with control cells
(Figure 5b). We also detected MMP7 secreted by casein
zymography in 3-MPA and control cells. The secretion of
MMP7 was suppressed in 3-MPA-treated cells compared
with control cells (Figure 5c).
We performed cellular proliferation, invasiveness, and
migratory assays to evaluate the biologic effects of 3-MPA-
treated cells. The cellular proliferation assay showed similargrowth curves for 3-MPA-treated and control cells, indicat-
ing that inhibition of GAD1 did not affect cellular prolifera-
tion (data not shown). The invasiveness assay showed that
the number of penetrating 3-MPA-treated cells decreased
compared with control cells (Figure 6a). The migratory
assay showed that the wounds in the 3-MPA-treated
cells closed later than in control cells (Figure 6b) when
we visually monitored the area of uniform wounds in con-
fluent cell cultures.
Expression of GAD1 and clinicopathological variables of
primary OSCCs
Table 1 shows the correlations between the clinicopatho-
logic characteristics of patients with OSCC and the status
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system. Among the clinical classifications, GAD1-positive
OSCCs were significantly (P = 0.011) correlated with
regional lymph node metastasis.Discussion
GAD1 was overexpressed in OSCC-derived cell lines
and new functions of GAD1 were related closely to
cellular invasiveness and migration in oral cancer. GAD1
knockdown and 3-MPA-treated cells had suppressed β-
catenin levels in the nucleus and secretion of MMP7.
Surprisingly, GAD1-positive OSCCs were significantly
(P < 0.05) associated with regional lymph node metasta-
sis (Table 1).
GAD isoforms, GAD1 and GAD2, are derived from a
common ancestral gene [34]. GAD2 is localized to the
nerve terminal and is reversibly bound to the membrane
of synaptic vesicles, which has been linked with lower birth
weights and additional risk for metabolic diseases [35],
whereas GAD1 is a cytosolic enzyme distributed through-
out the organs and central nervous system [36]. The en-
zymatic functions of GAD1 and GAD2 are almost similar;
however, their functions remain unclear in cancer tissues
[37]. Since our previous microarray data showed that
GAD1 is up-regulated significantly in OSCCs [38], we fo-
cused on GAD1 in the current study.
β-catenin plays crucial and diverse roles in cadherin-
mediated cell-cell adhesion, Wnt signal transduction, gene
activation, and tumoral formation [39-41]. Although the
interaction mechanism between GAD1 and β-catenin has
not yet been reported, the current data suggested that
GAD1 expression controls β-catenin localization. β-catenin
in nuclei binds to the TCF/LEF in several types of cancers
for transcriptional activation of downstream genes, such as
MMP7, cyclinD1, and c-myc [42-46], which play important
roles in carcinogenesis and metastasis.
We then investigated MMP7 secretion, a downstream
candidate of GAD1/β-catenin interaction, because MMP7
often is overexpressed in human cancer tissues and associ-
ated with cancer cell invasiveness by proteolytic cleavage of
the ECM substrates and degradation of basement mem-
brane proteins [47-50]. Interestingly, we found that GAD1
knockdown and 3-MPA-treated cells inhibited MMP7 se-
cretion by decreasing nuclear translocation of β-catenin.
We speculated that the GAD1/β-catenin/MMP7 interac-
tion affects cancer cell behaviors, such as cellular invasive-
ness and migration. In addition to the in vitro data that
down-regulation of GAD1 led to low cellular invasiveness
and migratory abilities, patients with GAD1-negative OSCC
had a low risk of regional lymph node metastasis. Consist-
ent with our hypothesis, the GAD1/β-catenin/MMP7 inter-
action is correlated closely with metastasis both in vitro and
in vivo.Conclusion
Our results showed that oral cancer carcinogenesis over-
expression of GAD1 occurs frequently and that it might
be closely associated with invasion and metastasis of
OSCC by β-catenin translocation and MMP7 activation,
while further studies are needed to research the GAD1/
β-catenin/MMP7 interaction, the current data indicated
that GAD1 is likely a molecular marker for early detection
of lymph node metastasis and an efficacious treatment tar-
get for preventing cancer metastasis in OSCCs.
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